

Wieslab Request Form – Monitoring of Biopharmaceuticals



ORDERING INFORMATION

Requesting Clinic – **required**

Postal address for test results

Invoice Address

Postal or email address for invoice. Only doctors, labs, or hospitals can be invoiced

Ref. Number or Cost Center

REQUESTING DOCTOR

Name

Email

Phone

Date of last drug administration/Other comments

TERMS & CONDITIONS

View our terms and conditions: svarlifescience.com/wieslab-terms

PATIENT DATA

Full Name

Gender Woman
 Man Other

Birth Date, Identity Number

Sampling Date

The health care provider submitting the sample(s) and this Request Form hereby confirms that the patient (or the patient's guardian or trustee, if applicable) has been informed about the [Terms and Conditions](#) regarding sample handling and storage.

No, the patient does not consent to save the sample.

The patient is currently unable to consent to the retention of the sample(s).

INSTRUCTIONS

C = Concentration of biopharmaceutical.

R = Concentration and ADA testing.

A = ADA testing.

- The sample should be drawn at trough value, just before the next drug administration. Trough value is the minimal drug concentration at steady state and when the variations of drug levels in serum are the lowest.
- Presence of drug in the test sample may prevent the detection of ADA (Anti-Drug Antibodies).

Send Frozen Send Cold Can be sent at room temperature

Comprehensive instructions available at svarlifescience.com/sampling-instructions

SHIPPING

Send to

Wieslab AB
Lundvägen 151, 212 24 Malmö, Sweden

CONTACT

Phone +46 (0)40-53 76 60

Email: diagnostic.services@svarlifescience.com

Updated: 2025-12-08

Tests

B/T CELL INHIBITORS

c 615 Abatacept

At least 0.7 mL serum per sample.

c 603 Rituximab

R At least 0.7 mL serum per sample.

COMPLEMENT INHIBITORS

c 613 Eculizumab

At least 0.7 mL serum per sample.

CYTOKINE INHIBITORS

c 607 Tocilizumab

R At least 0.7 mL serum per sample.

c 605 Ustekinumab

R At least 0.7 mL serum per sample. ADA testing performed only if biopharmaceutical concentration is low.

INTEGRIN INHIBITORS

c 136 Natalizumab

R At least 0.7 mL serum per sample.

c 138 Vedolizumab

R At least 0.7 mL serum per sample. ADA testing performed only if biopharmaceutical concentration is low.

TNF-ALPHA INHIBITORS

c 126 Adalimumab

R At least 0.7 mL serum per sample. ADA testing performed only if biopharmaceutical concentration is low.

c 132 Certolizumab

At least 0.5 mL serum per sample.

c 128 Etanercept

At least 0.5 mL serum per sample.

c 130 Golimumab

R At least 0.7 mL serum per sample. ADA testing performed only if biopharmaceutical concentration is low.

c 124 Infliximab

R At least 0.7 mL serum per sample. ADA testing performed only if biopharmaceutical concentration is low.

OTHER

A 105 Erythropoietin

At least 1 mL serum per sample.